GLP-1 Agonist Semaglutide Successfully Manages Rare Mitochondrial Diabetes in Adolescent

Mitochondrial diabetes is a rare and complex form of diabetes, often requiring intensive management with dietary interventions, oral hypoglycemic agents, and frequently, insulin therapy. Patients with genetic conditions like MELAS (Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like episodes), specifically due to the m.3243A>G mutation, present unique challenges in glycemic control. While novel treatments are emerging, their efficacy and safety in this specific population, especially in pediatric cases, are not well-characterized.

The introduction of semaglutide led to a dramatic improvement in the patient's glycemic control. Her HbA1c, a key marker of long-term blood sugar, decreased significantly from an initial 13.7% (126mmol/mol) to a well-controlled 5.6% (38mmol/mol) over the 7-month treatment period. Insulin therapy was completely ceased within just 5 days of starting semaglutide. Continuous Glucose Monitoring (CGM) data, collected over a 5-month follow-up, consistently demonstrated that the patient's glucose levels met established glycaemic targets. Importantly, the treatment was well tolerated, with no reported episodes of lactic acidosis, a critical concern in mitochondrial disorders. The patient's HbA1c dramatically decreased from 13.7% (126mmol/mol) to 5.6% (38mmol/mol) over a 7-month period, demonstrating exceptional glycemic control.